New products
Senseonics begins first human trial of Freedom CGM
Senseonics Holdings has initiated a first-in-human clinical trial of Freedom, its investigational continuous glucose monitoring (CGM) system. The study will evaluate the device's safety and performance in patients with diabetes. Senseonics is a key player in implantable glucose monitoring technology.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network